Nasopharyngeal Cancer Risk Assessment by Country or Region Worldwide from 1990 to 2019

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2024 Jul 18

PMID 39026191

Authors

Xian Wei

Biaoyou Chen

Zihao Wang

Peng Zhao

Xuwei Duan

Affiliations

Soon will be listed here.

Abstract

Background: Nasopharyngeal carcinoma (NPC) is 22nd most common cancer that occurs all over the world, but the prevalence rate can exhibit significant geographical differences. The Global Burden of Disease (GBD) database provides data related to the incidence, mortality, and disease burden of NPC worldwide from 1990 to 2019. We have designed this study in order to evaluate the potential effectiveness of health care policies and strategies for NPC prevention, diagnosis and treatment in different countries or regions around the world.

Methods: We used for the first time two distinct indicators, EAPC-ASIR and EACP-ASDR, to perform cluster analysis on 200 countries or regions around the world.

Results: 200 countries or regions could be divided into five diverse groups. Group 1: The incidence rate showed an increasing trend whereas the mortality rate depicted a decreasing trend. Group 2: Morbidity as well as mortality showed a slight increase; Group 3: Morbidity as well as mortality increased significantly; Group 4: Morbidity and mortality decreased significantly; Group 5: Both morbidity as well as mortality decreased slightly. Moreover, in the context of a global decline in NPC incidence, mortality and disease burden, Group 3 countries, including: "Turkmenistan", "Bosnia and Herzegovina", "Dominican Republic", "Bulgaria", "Lesotho", "Cabo Verde", "Romania", "Cuba", "Jamaica", "Azerbaijan", "Uzbekistan", "Chad", "Belize" and "Ukraine" displayed a significant increase in morbidity, mortality, and disease burden, thus indicating a dangerous trend.

Conclusion: It is suggested that the medical and health policies formulated by the countries in Group 3 for NPC, as well as their capacity for conducting censuses, preventing, diagnosing, and treating diseases, need to be substantially strengthened.

References

Xu J, Wei X, Wang Y, Wang F . Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022; 14:17588359221096214. PMC: 9083041. DOI: 10.1177/17588359221096214. View

Zeng Y, Zhang L, Wu Y, Huang Y, Huang N, Li J . Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985; 36(5):545-7. DOI: 10.1002/ijc.2910360505. View

Lim K, Ghazali S, Lim H, Kee C, Cheah Y, Singh B . Tobacco use and other aspects related to smoking among school-going adolescents aged 13-15 years in Malaysia: Analysis of three cross-sectional nationally representative surveys in 2003, 2009 and 2016. Tob Induc Dis. 2020; 18:80. PMC: 7528268. DOI: 10.18332/tid/127231. View

Lam W, Jiang P, Chan K, Cheng S, Zhang H, Peng W . Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2018; 115(22):E5115-E5124. PMC: 5984543. DOI: 10.1073/pnas.1804184115. View

Fay M, Tiwari R, Feuer E, Zou Z . Estimating average annual percent change for disease rates without assuming constant change. Biometrics. 2006; 62(3):847-54. DOI: 10.1111/j.1541-0420.2006.00528.x. View

Lee A, Ng W, Chan J, Corry J, Makitie A, Mendenhall W . Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019; 79:101890. DOI: 10.1016/j.ctrv.2019.101890. View

Young L, Yap L, Murray P . Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016; 16(12):789-802. DOI: 10.1038/nrc.2016.92. View

Rahman A, Mambali M, Keshavarzi F, Baig M, Hariadha E, Farrukh M . Evaluation of Smoking Prevalence, Secondhand Smoke Exposure, Attitudes of Tobacco Control, and Smoking Cessation Knowledge among Pharmacy and Medical Students in a Private University, Malaysia. J Pharm Bioallied Sci. 2022; 14(1):38-45. PMC: 9245913. DOI: 10.4103/jpbs.jpbs_334_21. View

Reffai A, Mesmoudi M, Derkaoui T, Ghailani Nourouti N, Barakat A, Sellal N . Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. Cancer Control. 2021; 28:10732748211050587. PMC: 8529313. DOI: 10.1177/10732748211050587. View

10.

. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204-1222. PMC: 7567026. DOI: 10.1016/S0140-6736(20)30925-9. View

11.

Zhang L, Wang L, Wu Y, Zhou C, Zhang L, He L . Assessment and management of radiation-induced trismus in patients with nasopharyngeal carcinoma: a best practice implementation project. JBI Evid Implement. 2022; 21(3):208-217. DOI: 10.1097/XEB.0000000000000355. View

12.

Miller J, Le Q, Pinsky B, Wang H . Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide. J Natl Cancer Inst. 2020; 113(7):852-862. DOI: 10.1093/jnci/djaa198. View

13.

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

14.

Chang E, Ye W, Zeng Y, Adami H . The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1035-1047. DOI: 10.1158/1055-9965.EPI-20-1702. View

15.

Leong Y, Soon Y, Lee K, Wong L, Tham I, Ho F . Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: A meta-analysis. Head Neck. 2017; 40(3):622-631. DOI: 10.1002/hed.24993. View

16.

Au K, Ngan R, Ng A, Poon D, Ng W, Yuen K . Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018; 77:16-21. DOI: 10.1016/j.oraloncology.2017.12.004. View

17.

Chan K, Woo J, King A, Zee B, Lam W, Chan S . Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017; 377(6):513-522. DOI: 10.1056/NEJMoa1701717. View

18.

Yip P, Mok K, Ho H, Lee W, Wong A, Lau C . Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Survivors in the Modern Treatment Era - The Early and Late Effects of Radiation and Cisplatin. Clin Oncol (R Coll Radiol). 2021; 34(4):e160-e167. DOI: 10.1016/j.clon.2021.10.013. View

19.

Zhang J, Jia L, Tsang C, Tsao S . EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma. Adv Exp Med Biol. 2017; 1018:75-90. DOI: 10.1007/978-981-10-5765-6_6. View

20.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View